US Pharma MarketingThe post BD uplifts FY26 revenue outlook based on steady portfolio performance appeared first on Medical Device Network.
BD uplifts FY26 revenue outlook based on steady portfolio performance
The uplifted FY26 outlook reflects a reversal on Q1 FY26, in which BD trimmed its outlook due to impacts from the sale of its diagnostics unit to Waters. The uplifted FY26 outlook reflects a reversal on Q1 FY26, in which BD trimmed its outlook due to impacts from the sale of its diagnostics unit to Waters. BD’s revised EPS outlook for FY26 marks a u-turn from Q1 FY26, in which it trimmed its outlook for the year. JHVEPhoto / Shutterstock.com In a reversal from its previously reported quarter, Becton Dickinson and Company (BD) has lifted its fiscal year 2026 (FY26)…
The uplifted FY26 outlook reflects a reversal on Q1 FY26, in which BD trimmed its outlook due to impacts from the sale of its diagnostics unit to Waters.
Source: Medical Device Network